Skip to main content
Erschienen in: American Journal of Clinical Dermatology 6/2004

01.12.2004 | Therapy in Practice

Topical Therapy for Fungal Infections

verfasst von: Professor Amber A. Kyle, Mark V. Dahl

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 6/2004

Einloggen, um Zugang zu erhalten

Abstract

Fungi often infect the skin surface and subsequently invade the stratum corneum to avoid being shed from the skin surface by desquamation. Pharmacologic agents applied to the surface of the skin in the form of creams, lotions, or sprays, readily penetrate into the stratum corneum to kill the fungi (fungicidal agents), or at least render them unable to grow or divide (fungistatic agents). Thus, topical therapies work well to rid the skin of topical fungi and yeasts. Azole drugs such as miconazole, clotrimazole, and ketoconazole are fungistatic, limiting fungal growth but depending on epidermal turnover to shed the still-living fungus from the skin surface. Allylamines and benzylamines such as terbinafine, naftifine, and butenafine are fungicidal, actually killing the fungal organisms. Fungicidal drugs are often preferred over fungistatic drugs for treatment of dermatophytic fungal infections, since treatment times as short as one application daily for 1 week are associated with high cure rates. Furthermore, patients often stop treatments when the skin appears healed, usually after about a week of treatment. If this short-term treatment is stopped, fungi recur more often when fungistatic, rather than fungicidal, drugs have been used. Yeast infections such as those caused by Candida albicans respond less well to allylamine drugs. The azole drugs are often preferred for these types of infections. Nail infections are difficult to cure with topical therapies because the infections usually occur under the nail instead of on top of it and products penetrate poorly, if at all, through the nail plate. Infections of hair follicles, nails, and widespread infections often require systemic treatments. Antifungal agents are compounded into many different types of vehicles. Patients often prefer to treat weeping infections with spray formulations. Most physicians prescribe branded products in cream or lotion bases. Cost is a factor dictating prescription choice, especially since most products work well regardless of mechanism of action. Cost becomes especially important when infections involve large areas of the body surface. This article reviews various treatments of cutaneous fungal infections, with special emphasis on cure rates and rationales for choosing particular products.
Literatur
1.
Zurück zum Zitat Gupta AK, Einarson TR, Summerbell RC, et al. An overview of topical antifungal therapy in dermatomycosis: a North American perspective. Drugs 1998; 55: 645–74PubMedCrossRef Gupta AK, Einarson TR, Summerbell RC, et al. An overview of topical antifungal therapy in dermatomycosis: a North American perspective. Drugs 1998; 55: 645–74PubMedCrossRef
2.
Zurück zum Zitat Dahl MV. Chronic dermatophytosis: what is special about Trichophyton rubrum. Adv Dermatol 1994; 9: 97–111PubMed Dahl MV. Chronic dermatophytosis: what is special about Trichophyton rubrum. Adv Dermatol 1994; 9: 97–111PubMed
3.
Zurück zum Zitat Jones HE, Reinhardt JH, Rinaldi MG. Acquired immunity to dermatophytes. Arch Dermatol 1974; 109: 840–8PubMedCrossRef Jones HE, Reinhardt JH, Rinaldi MG. Acquired immunity to dermatophytes. Arch Dermatol 1974; 109: 840–8PubMedCrossRef
4.
Zurück zum Zitat Dahl MV. Immunological resistance to dermatophyte infections. Adv Dermatol 1987; 2: 305–20PubMed Dahl MV. Immunological resistance to dermatophyte infections. Adv Dermatol 1987; 2: 305–20PubMed
6.
Zurück zum Zitat Balfour JA. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial mycoses. Drugs 1992; 43: 259–84PubMedCrossRef Balfour JA. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial mycoses. Drugs 1992; 43: 259–84PubMedCrossRef
7.
Zurück zum Zitat Abdel-Rahman SM. Oral terbinafine: a new antifungal agent. Ann Pharmacother 1997; 31: 445–56PubMed Abdel-Rahman SM. Oral terbinafine: a new antifungal agent. Ann Pharmacother 1997; 31: 445–56PubMed
8.
Zurück zum Zitat Noguchi H. Effectiveness of treatment of severe tinea pedis with 1% terbinafine cream in members of the Japanese self-defense forces. Mycoses 1999; 42: 479–84PubMedCrossRef Noguchi H. Effectiveness of treatment of severe tinea pedis with 1% terbinafine cream in members of the Japanese self-defense forces. Mycoses 1999; 42: 479–84PubMedCrossRef
9.
Zurück zum Zitat Berman B. Efficacy of a 1-week, twice-daily regimen of terbinafine 1% cream in the treatment of interdigital tinea pedis: results of placebo-controlled, double-blind, multicenter trials. J Am Acad Dermatol 1992; 26: 956–60PubMedCrossRef Berman B. Efficacy of a 1-week, twice-daily regimen of terbinafine 1% cream in the treatment of interdigital tinea pedis: results of placebo-controlled, double-blind, multicenter trials. J Am Acad Dermatol 1992; 26: 956–60PubMedCrossRef
10.
11.
Zurück zum Zitat Rosen T. Anti-inflammatory activity of antifungal preparations. Int J Dermatol 1997; 36: 788–92PubMedCrossRef Rosen T. Anti-inflammatory activity of antifungal preparations. Int J Dermatol 1997; 36: 788–92PubMedCrossRef
13.
Zurück zum Zitat Tschen E. Treatment of interdigital tinea pedis with a 4-week once-daily regimen of butenafine hydrochloride 1% cream. J Am Acad Dermatol 1997; 36 (2 Pt 1): 9S-14CrossRef Tschen E. Treatment of interdigital tinea pedis with a 4-week once-daily regimen of butenafine hydrochloride 1% cream. J Am Acad Dermatol 1997; 36 (2 Pt 1): 9S-14CrossRef
14.
Zurück zum Zitat Lesher JL. Butenafine 1% cream in the treatment of tinea cruris: a multicenter, vehicle-controlled, double-blind trial. J Am Acad Dermatol 1997; 36: (2 Pt 1): 20S-24CrossRef Lesher JL. Butenafine 1% cream in the treatment of tinea cruris: a multicenter, vehicle-controlled, double-blind trial. J Am Acad Dermatol 1997; 36: (2 Pt 1): 20S-24CrossRef
15.
Zurück zum Zitat Greer DL. A randomized trial to assess once-daily topical treatment of tinea corporis with butenafine, a new antifungal agent. J Am Acad Dermatol 1997; 37: 231–5PubMedCrossRef Greer DL. A randomized trial to assess once-daily topical treatment of tinea corporis with butenafine, a new antifungal agent. J Am Acad Dermatol 1997; 37: 231–5PubMedCrossRef
16.
Zurück zum Zitat Nahm WK. The antifungal agent butenafine manifests anti-inflammatory activity in vivo. J Am Acad Dermatol 1999; 41: 203–6PubMedCrossRef Nahm WK. The antifungal agent butenafine manifests anti-inflammatory activity in vivo. J Am Acad Dermatol 1999; 41: 203–6PubMedCrossRef
17.
Zurück zum Zitat Bremm KD. Modulation of leukotriene metabolism from human polymorphonuclear granulocytes by bifonazole. Mycoses 1991; 34: 41–5PubMedCrossRef Bremm KD. Modulation of leukotriene metabolism from human polymorphonuclear granulocytes by bifonazole. Mycoses 1991; 34: 41–5PubMedCrossRef
18.
Zurück zum Zitat Sud IJ. Mechanisms of action of the antimycotic imidazoles. J Invest Dermatol 1981; 76: 438–41PubMedCrossRef Sud IJ. Mechanisms of action of the antimycotic imidazoles. J Invest Dermatol 1981; 76: 438–41PubMedCrossRef
19.
Zurück zum Zitat Lupetti A. Molecular basis of resistance to azole antifungals. Trends Mol Med 2002; 8: 76–81PubMedCrossRef Lupetti A. Molecular basis of resistance to azole antifungals. Trends Mol Med 2002; 8: 76–81PubMedCrossRef
20.
Zurück zum Zitat Scheman J, Severson DL. Pocket guide to medications used in dermatology. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 1999 Scheman J, Severson DL. Pocket guide to medications used in dermatology. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 1999
21.
Zurück zum Zitat Beetens JR. Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo. Biochem Pharmacol 1986; 35: 883–91PubMedCrossRef Beetens JR. Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo. Biochem Pharmacol 1986; 35: 883–91PubMedCrossRef
22.
Zurück zum Zitat Hegemann L. Direct interaction of antifungal azole-derivatives with calmodulin: a possible mechanism for their therapeutic activity. J Invest Dermatol 1993; 100: 343–6PubMedCrossRef Hegemann L. Direct interaction of antifungal azole-derivatives with calmodulin: a possible mechanism for their therapeutic activity. J Invest Dermatol 1993; 100: 343–6PubMedCrossRef
23.
Zurück zum Zitat Bogaert H, Cordero C, Ollague W, et al. Multicentre double-blind clinical trials of ciclopirox olamine cream 1% in the treatment of tinea pedis and tinea cruris. J Int Med Res 1986; 14: 210–6PubMed Bogaert H, Cordero C, Ollague W, et al. Multicentre double-blind clinical trials of ciclopirox olamine cream 1% in the treatment of tinea pedis and tinea cruris. J Int Med Res 1986; 14: 210–6PubMed
24.
Zurück zum Zitat Zaug M, Bergstraesser M. Amorolfine in the treatment of onychomycosis and dermatomycosis (an overview). Clin Exp Dermatol 1992; 17: 61–70PubMedCrossRef Zaug M, Bergstraesser M. Amorolfine in the treatment of onychomycosis and dermatomycosis (an overview). Clin Exp Dermatol 1992; 17: 61–70PubMedCrossRef
25.
Zurück zum Zitat Guerst JF. Comparison between undecylenic acid and tolnaftate in the treatment of tinea pedis. Cutis 1980; 25: 544–6 Guerst JF. Comparison between undecylenic acid and tolnaftate in the treatment of tinea pedis. Cutis 1980; 25: 544–6
26.
Zurück zum Zitat Tanuma H, Doi M, Ohta Y, et al. Betenafine hydrochloride (Mentax) cream for the treatment of hyperkeratotic type tinea pedis and its transfer into the horny layer with or without concomitant application of 20% urea ointment (Keratinamin). Mycosis 2001; 44: 287–9CrossRef Tanuma H, Doi M, Ohta Y, et al. Betenafine hydrochloride (Mentax) cream for the treatment of hyperkeratotic type tinea pedis and its transfer into the horny layer with or without concomitant application of 20% urea ointment (Keratinamin). Mycosis 2001; 44: 287–9CrossRef
27.
Zurück zum Zitat Elewski BE, Haley HR, Robbins CM. The use of 40% urea cream in the treatment of moccasin tinea pedis. Cutis 2004; 73 (5): 355–7PubMed Elewski BE, Haley HR, Robbins CM. The use of 40% urea cream in the treatment of moccasin tinea pedis. Cutis 2004; 73 (5): 355–7PubMed
28.
Zurück zum Zitat Bergstresser PR, Elewski B, Hanifin J, et al. Topical terbinafine and clotrimazole in interdigital tinea pedis: a multicenter comparison of cures and relapse rates with 1- and 4-week treatment regimens. J Am Acad Dermatol 1993; 28: 648–51PubMedCrossRef Bergstresser PR, Elewski B, Hanifin J, et al. Topical terbinafine and clotrimazole in interdigital tinea pedis: a multicenter comparison of cures and relapse rates with 1- and 4-week treatment regimens. J Am Acad Dermatol 1993; 28: 648–51PubMedCrossRef
29.
Zurück zum Zitat Ablon G, Rosen T, Spedale J. Comparative efficacy of naftifine, oxiconazole, and terbinafine in the short term treatment of tinea pedis. Int J Dermatol 1996; 35: 591–3PubMedCrossRef Ablon G, Rosen T, Spedale J. Comparative efficacy of naftifine, oxiconazole, and terbinafine in the short term treatment of tinea pedis. Int J Dermatol 1996; 35: 591–3PubMedCrossRef
30.
Zurück zum Zitat Evans EG. A comparison of terbinafine 1% cream given for one week with clotrimazole (Canesten) 1% cream given for four weeks in the treatment of tinea pedis. Br J Dermatol 1994; 130 Suppl. 43: 1S-4CrossRef Evans EG. A comparison of terbinafine 1% cream given for one week with clotrimazole (Canesten) 1% cream given for four weeks in the treatment of tinea pedis. Br J Dermatol 1994; 130 Suppl. 43: 1S-4CrossRef
31.
Zurück zum Zitat Evans EG. Comparison of terbinafine and clotrimazole in treating tinea pedis. BMJ 1993; 307: 545–7 Evans EG. Comparison of terbinafine and clotrimazole in treating tinea pedis. BMJ 1993; 307: 545–7
32.
Zurück zum Zitat Haria M, Bryson HM. Amorolifine: a review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other topical fungal infections. Drugs 1995; 49: 103–20PubMedCrossRef Haria M, Bryson HM. Amorolifine: a review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other topical fungal infections. Drugs 1995; 49: 103–20PubMedCrossRef
33.
Zurück zum Zitat Alomar C, Bassas S, Casas M, et al. Multi-centre double-blind trial on the efficacy and safety of sertaconazole 2% cream in comparison with miconazole 2% cream on patients suffering from cutaneous mycoses. Arzneimittelforschung 1992; 42 (5A): 767–73PubMed Alomar C, Bassas S, Casas M, et al. Multi-centre double-blind trial on the efficacy and safety of sertaconazole 2% cream in comparison with miconazole 2% cream on patients suffering from cutaneous mycoses. Arzneimittelforschung 1992; 42 (5A): 767–73PubMed
34.
Zurück zum Zitat Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000 Oct; 43 Suppl. 4: S57–69CrossRef Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000 Oct; 43 Suppl. 4: S57–69CrossRef
35.
Zurück zum Zitat Syed TA, Ahmadpour OA, Ahmad SA, et al. Management of toenail onychomycosis with 2% butenafine and 20% urea cream: a placebo-controlled, double-blind study. J Dermatol 1998; 25 (10): 648–52PubMed Syed TA, Ahmadpour OA, Ahmad SA, et al. Management of toenail onychomycosis with 2% butenafine and 20% urea cream: a placebo-controlled, double-blind study. J Dermatol 1998; 25 (10): 648–52PubMed
36.
Zurück zum Zitat Baran R. Topical amorolfine in 15 months combined with 12 weeks of oral terbinafine: a cost effective treatment for onychomycosis. Br J Dermatol 2001; 145 Suppl. 60: 15S-9SPubMed Baran R. Topical amorolfine in 15 months combined with 12 weeks of oral terbinafine: a cost effective treatment for onychomycosis. Br J Dermatol 2001; 145 Suppl. 60: 15S-9SPubMed
37.
Zurück zum Zitat Sanchez JL, Torres VM. Double-blind efficacy study of selenium sulfide in tinea versicolor. J Am Acad Dermatol 1984; 11: 235–8PubMedCrossRef Sanchez JL, Torres VM. Double-blind efficacy study of selenium sulfide in tinea versicolor. J Am Acad Dermatol 1984; 11: 235–8PubMedCrossRef
38.
Zurück zum Zitat Greer DL. Successful treatment of tinea capitis with 2% ketoconazole shampoo. Int J Dermatol 2000; 39 (4): 302–4PubMedCrossRef Greer DL. Successful treatment of tinea capitis with 2% ketoconazole shampoo. Int J Dermatol 2000; 39 (4): 302–4PubMedCrossRef
39.
Zurück zum Zitat Hull CA, Johnson SM. A double-blind comparative study of sodium sulfacetamide lotion 10% versus selenium sulfide lotion 2.5% in the treatment of pityriasis (tinea) versicolor. Cutis 2004; 73 (6): 425–9PubMed Hull CA, Johnson SM. A double-blind comparative study of sodium sulfacetamide lotion 10% versus selenium sulfide lotion 2.5% in the treatment of pityriasis (tinea) versicolor. Cutis 2004; 73 (6): 425–9PubMed
40.
Zurück zum Zitat Jones HE, Reinhardt JH, Rinaldi MG. Immunologic susceptibility to chronic dermatophytosis. Arch Dermatol 1974; 110 (2): 213–20PubMedCrossRef Jones HE, Reinhardt JH, Rinaldi MG. Immunologic susceptibility to chronic dermatophytosis. Arch Dermatol 1974; 110 (2): 213–20PubMedCrossRef
Metadaten
Titel
Topical Therapy for Fungal Infections
verfasst von
Professor Amber A. Kyle
Mark V. Dahl
Publikationsdatum
01.12.2004
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 6/2004
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200405060-00009

Weitere Artikel der Ausgabe 6/2004

American Journal of Clinical Dermatology 6/2004 Zur Ausgabe

Acknowledgments

Acknowledgment

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.